Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 4:15 PM ET
Travere Therapeutics Inc (TVTX) Statistics
Travere Therapeutics (TVTX) has a market cap of $4.86B and an enterprise value of $5.35B. Revenue grew 49.38% over the last 12 months from the 12 months before. Its share count is down 7.79% from a year earlier.
Total Valuation
Enterprise value is 10.00% above the market cap, as debt exceeds cash.
| Market Cap | $4.86B |
|---|---|
| Enterprise Value | $5.35B |
| Latest price (Nov 17, 2026) | $51.10 |
Key Dates
| Last Earnings Date | Nov 2, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.4x and 214.1x. Its year-end P/S ranged from 3.4x to 8.2x from 2016 to 2025.
| P/S Ratio | 7.4x |
|---|---|
| Forward P/S | 6.4x |
| P/B Ratio | 214.1x |
| P/FCF Ratio | 53.0x |
| P/OCF Ratio | 27.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 58.4x free cash flow.
| EV / Sales | 8.2x |
|---|---|
| EV / FCF | 58.4x |
Price Statistics
The stock is up 48.12% over 52 weeks and trades 7.63% below its 50-day average.
| Beta (1Y) | 1.26 |
|---|---|
| 52-Week Change | +48.12% |
| 1-Month Change | +1.21% |
| 3-Month Change | -22.53% |
| 6-Month Change | +20.92% |
| 5-Year Change | +74.90% |
| 10-Year Change | +167.32% |
| Total Return (1Y) | +48.12% |
| Total Return (3Y CAGR) | +105.91% |
| Total Return (5Y CAGR) | +11.75% |
| Return vs SPY (1Y) | +30.39% |
| Max Drawdown (1Y) | -33.49% |
| Max Drawdown (3Y) | -46.44% |
| Sharpe Ratio (1Y) | 0.60 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $55.32 |
| 200-Day Average | $47.87 |
| 52-Week Range | $22.59 to $68.73 |
| RSI (14 Days) | 46.6 |
| Average Volume (20 Days) | 2.20M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.00x current liabilities, and total debt is 27.00x shareholder equity.
| Current Ratio | 3.00x |
|---|---|
| Quick Ratio | 2.95x |
| Debt / Equity | 27.00x |
| Debt / FCF | 6.69x |
| Interest Coverage | -17.01x |
Returns and Efficiency
Return on invested capital is -23.06% over the last 12 months, against a 5-year average of -48.92%.
| Return on Equity (ROE) | -538.02% |
|---|---|
| Return on Assets (ROA) | -14.32% |
| Return on Invested Capital (ROIC) | -23.06% |
| Return on Capital Employed (ROCE) | -23.67% |
| ROA (5Y Average) | -27.41% |
| ROIC (5Y Average) | -48.92% |
| Asset Turnover | 0.94x |
| Inventory Turnover | 3.74x |
| Receivables Turnover | 6.92x |
| Cash Conversion Cycle | 29 days |
Scores
TVTX has an Altman Z-Score of 1.66, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.66 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $651.03M over the last 12 months.
| Revenue | $651.03M |
|---|---|
| Revenue Growth (YoY) | +49.38% |
| Gross Profit | $616.67M |
| Operating Income | -$133.49M |
| Pretax Income | -$159.72M |
| Net Income | -$121.51M |
| EBITDA | -$98.07M |
| EBIT | -$150.85M |
| Reported EPS (TTM) | -$0.50 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 2.66% of the $848.23M in total assets.
| Cash and Equivalents | $123.54M |
|---|---|
| Total Debt | $609.82M |
| Net Debt | $486.28M |
| Net Debt Per Share | $5.14 |
| Working Capital | $422.53M |
| Shareholder Equity | $22.58M |
| Book Value Per Share | $0.24 |
| Tangible Book Value | -$141.52M |
| Total Assets | $848.23M |
| Total Liabilities | $825.64M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $85.40M of capital spending, operating cash flow left $91.19M of free cash flow.
| Operating Cash Flow | $176.59M |
|---|---|
| Capital Expenditures | $85.40M |
| Free Cash Flow | $91.19M |
| FCF Per Share | $0.95 |
| Depreciation and Amortization | $52.78M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -20.50%.
| Gross Margin | 94.72% |
|---|---|
| Operating Margin | -20.50% |
| Pretax Margin | -24.53% |
| Net Margin | -18.66% |
| EBITDA Margin | -15.06% |
| EBIT Margin | -23.17% |
| FCF Margin | 14.01% |
| Gross Margin (5Y Average) | 95.95% |
Growth
Revenue grew 64.89% a year over 3 years.
| Revenue Growth (3Y CAGR) | +64.89% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.87% |
| Book Value Per Share Growth (2Y CAGR) | -30.41% |
| Tangible Book Per Share Growth (2Y CAGR) | -87.73% |
Dividends and Yields
TVTX does not pay a dividend. Its free cash flow yield is 1.89%.
| FCF Yield | 1.89% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 8 similar companies, TVTX has the 7th highest P/S and the 5th highest ROIC.
P/S RatioPeer median 13.1x
ROICPeer median -31.02%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.26%
| P/S Ratio | 7.4x vs 13.1x median |
|---|---|
| ROIC | -23.06% vs -31.02% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +49.38% vs +14.26% median |
Analyst Forecast
Consensus estimates put revenue growth at 52.25% and EPS growth at 145.35% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +52.25% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +145.35% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TVTX
What is TVTX's market cap?
Travere Therapeutics has a market cap of $4.86B. Its enterprise value, which adds debt and subtracts cash, is $5.35B.
How many shares of TVTX are outstanding?
Travere Therapeutics has 94.63M shares outstanding. The count is down 7.79% from a year earlier.
Does TVTX pay a dividend?
No. Travere Therapeutics does not pay a dividend.
How much debt does TVTX have?
Travere Therapeutics has $609.82M of total debt and $123.54M of cash and equivalents, a net debt position of $486.28M.
TVTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts